SMS Pharmaceuticals Limited (SMS Pharma) has announced the successful closure of the recent inspection by the USFDA at its Central Laboratory Analytical Services, Gagillapur, Hyderabad, with the receipt of the Establishment Inspection Report (EIR). 

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations, as previously intimated to the stock exchanges. The company has received the Establishment Inspection Report (EIR) with "No Action Indicated" (NAI) status, marking the closure of the audit. 

Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated: "The successful completion of the recent USFDA inspection underscores our unwavering commitment to the highest standards of quality, regulatory compliance, and operational excellence across our manufacturing and analytical facilities. This positive outcome reinforces the confidence of our global partners and stakeholders, while further enabling our